About the Authors
- Thomas Prukop
-
Roles Conceptualization, Data curation, Writing – original draft
Affiliations Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany, University Medical Center Göttingen, Institute of Clinical Pharmacology, Göttingen, Germany
- Jan Stenzel
-
Roles Data curation
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- Stephanie Wernick
-
Roles Data curation
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- Theresa Kungl
-
Roles Data curation
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- Magdalena Mroczek
-
Roles Data curation
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- Julia Adam
-
Roles Data curation
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- David Ewers
-
Roles Data curation
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- Serguei Nabirotchkin
-
Roles Conceptualization
Affiliation Pharnext, Issy-Les-Moulineaux, France
- Klaus-Armin Nave
-
Roles Conceptualization, Writing – review & editing
Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany
- Rodolphe Hajj
-
Roles Conceptualization, Writing – review & editing
Affiliation Pharnext, Issy-Les-Moulineaux, France
- Daniel Cohen
-
Roles Conceptualization, Writing – review & editing
Affiliation Pharnext, Issy-Les-Moulineaux, France
- Michael W. Sereda
-
Roles Conceptualization, Writing – original draft
* E-mail: sereda@em.mpg.de
Affiliations Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany, University Medical Center Göttingen, Department of Clinical Neurophysiology, Göttingen, Germany
Competing Interests
We have the following interests. This trial was financially supported by Pharnext, the employer of Serguei Nabirotchkin, Rodolphe Hajj and Daniel Cohen. DC, RH, MWS, TP and KAN submitted a patent based on this work: Full patent name: Early treatment of CMT disease Number: US2018/0000813. MWS, TP and KAN act as consultants to Pharnext. PXT3003 achieved a Phase 3 trial in CMT1A adult patients. There are no further patents related to this study, or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.